辛伐他汀治疗脂肪肝的临床疗效分析

A Curative Effect Analysis of Simvastatin-Treating Fatty liver

目的:探讨辛伐他汀治疗脂肪肝的的临床疗效。方法:120例脂肪肝患者随机分为两组,辛伐他汀治疗组60例采用辛伐他汀20mg,每天1次口服;血脂康治疗组60例采用血脂康600mg,每天2次口服。8周为1个疗程,共3个疗程,观察辛伐他汀治疗组与血脂康治疗组的临床疗效、治疗前后血脂和B超变化情况,另选择同期体检证明为正常的健康者70人作为对照组。结果:辛伐他汀治疗组总有效率(93.1%)与血脂康组(90.3%)相似(P>0.05);辛伐他汀治疗组和血脂康治疗组治疗后与治疗前相比血总胆固醇(TC)、甘油三脂(TG)、高密度脂蛋白(HDL-C)均明显改善(P<0.01),辛伐他汀治疗组改善优于血脂康组(P<0.05或P<0.01),辛伐他汀治疗组与血脂康治疗组两组治疗后肝功能与治疗前相比均明显改善(P<0.01),但辛伐他汀治疗组与血脂康治疗组两组治疗后相比无显著差异(P>0.05),未见严重不良反应。结论:辛伐他汀是治疗高血脂和脂肪肝的有效药物之一,且副作用少,安全性大,值得临床应用。

Objective： To probe into the clinical curative effect of Simvastatin Tablets in treating fatty liver. Method： 120 cases with fatty liver are divided at random into two groups. 60 cases of Simvastatin group take 20 ml Simvastatin rally every day; 60 cases of Xuezhikang group take 600 ml Xuezhikang daily, two times a day. Eight weeks as a course of medical treatment, the treatment demands three courses. The curative effect, the change of blood fat and B ultrasonic waves before and after the treatment of the two groups are observed. At the same time 70 healthy people are chosen as a contrasting group. Result： There exist similarities （P〉0.05） between Simvastatin group （93.1） and Xuezhikang group （ 90.3）; Simvastatin group and Xuezhikang group demonstrate a significant improvement in TC, TG and HDL-C after the treatment. Simvastatin group is better than Xuezhikang group （P〈 0.05 or P 〈 0.01）.Liver functions of the two groups improved greatly after the treatment （ P〈 0.01）. But there exist no significance between two groups after the treatment. （P〉0.05） and there are no serious side effects. Result： Simvastatin is one of the effective ways to treat high blood lipid and fatty liver, and it is also safe with little side effect and deserves to be used in clinical treatment.